Organon & Co. (OGN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.62B USD | Liabilities, Current |
| Cash and equivalents | 1.13B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.49B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.35B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.62B | $1.13B | (m) | $1.49B | $1.35B | (m) |
| 2026-03-31 | (m) | $2.50B | $1.12B | (m) | $1.38B | $1.37B | (m) |
| 2025-12-31 | (m) | $2.39B | $574.00M | (m) | $1.33B | $1.41B | (m) |
| 2025-09-30 | (m) | $2.68B | $672.00M | (m) | $1.48B | $1.49B | (m) |
| 2025-06-30 | (m) | $2.80B | $599.00M | (m) | $1.48B | $1.45B | (m) |
| 2025-03-31 | (m) | $2.62B | $547.00M | (m) | $1.46B | $1.36B | (m) |
| 2024-12-31 | (m) | $2.72B | $675.00M | (m) | $1.36B | $1.32B | (m) |
| 2024-09-30 | (m) | $2.79B | $763.00M | (m) | $1.69B | $1.38B | (m) |
| 2024-06-30 | (m) | $2.75B | $704.00M | (m) | $1.62B | $1.29B | (m) |
| 2024-03-31 | (m) | $2.54B | $575.00M | (m) | $1.55B | $1.26B | (m) |
| 2023-12-31 | (m) | $2.92B | $693.00M | (m) | $1.74B | $1.31B | (m) |
| 2023-09-30 | (m) | $2.49B | $414.00M | (m) | $1.65B | $1.19B | (m) |
| 2023-06-30 | (m) | $2.39B | $326.00M | (m) | $1.67B | $1.20B | (m) |
| 2023-03-31 | (m) | $2.35B | $459.00M | (m) | $1.45B | $1.12B | (m) |
| 2022-12-31 | (m) | $2.51B | $706.00M | (m) | $1.48B | $1.00B | (m) |
| 2022-09-30 | (m) | $2.33B | $499.00M | (m) | $1.44B | $879.00M | (m) |
| 2022-06-30 | (m) | $2.40B | $545.00M | (m) | $1.49B | $950.00M | (m) |
| 2022-03-31 | (m) | $2.31B | $694.00M | (m) | $1.32B | $946.00M | (m) |
| 2021-12-31 | (m) | $2.60B | $737.00M | (m) | $1.38B | $915.00M | (m) |
| 2021-09-30 | (m) | $3.13B | $1.01B | (m) | $1.50B | $918.00M | (m) |
| 2021-06-30 | (m) | $2.98B | $730.00M | (m) | $1.51B | $871.00M | (m) |
| 2021-06-03 | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.88B | $141.00M | (m) | $1.01B | $924.00M | (m) |
| 2020-12-31 | (m) | $2.67B | $12.00M | (m) | $1.04B | $913.00M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |